HC Wainwright Estimates MeiraGTx FY2025 Earnings

MeiraGTx Holdings PLC (NASDAQ:MGTX) – Investment analysts at HC Wainwright issued their FY2025 EPS estimates for MeiraGTx in a research report issued to clients and investors on Monday, November 24th. HC Wainwright analyst M. Kapoor anticipates that the company will earn ($2.21) per share for the year. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for MeiraGTx’s current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for MeiraGTx’s Q4 2025 earnings at ($0.60) EPS, Q1 2026 earnings at ($0.61) EPS, Q2 2026 earnings at ($0.59) EPS, Q3 2026 earnings at ($0.61) EPS, Q4 2026 earnings at ($0.62) EPS and FY2026 earnings at ($2.43) EPS.

A number of other research firms also recently commented on MGTX. Chardan Capital reaffirmed a “buy” rating and issued a $35.00 price target on shares of MeiraGTx in a research note on Tuesday, November 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of MeiraGTx in a report on Wednesday, October 8th. Royal Bank Of Canada boosted their target price on shares of MeiraGTx from $12.00 to $16.00 and gave the company an “outperform” rating in a research report on Friday, November 14th. Wall Street Zen lowered shares of MeiraGTx from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Finally, Piper Sandler lifted their price objective on shares of MeiraGTx from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $26.00.

MeiraGTx Price Performance

Shares of NASDAQ MGTX opened at $8.20 on Wednesday. The business has a fifty day moving average price of $8.30 and a two-hundred day moving average price of $7.50. The stock has a market capitalization of $660.02 million, a PE ratio of -3.89 and a beta of 1.35. The company has a debt-to-equity ratio of 26.29, a current ratio of 0.22 and a quick ratio of 0.22. MeiraGTx has a fifty-two week low of $4.55 and a fifty-two week high of $9.73.

MeiraGTx (NASDAQ:MGTX) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.12). MeiraGTx had a negative net margin of 615.27% and a negative return on equity of 1,065.47%. The company had revenue of $0.41 million during the quarter, compared to analyst estimates of $7.71 million.

Institutional Investors Weigh In On MeiraGTx

Large investors have recently modified their holdings of the company. State of Alaska Department of Revenue acquired a new position in MeiraGTx in the third quarter valued at $33,000. BNP Paribas Financial Markets raised its position in shares of MeiraGTx by 43.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,810 shares of the company’s stock worth $31,000 after acquiring an additional 1,466 shares in the last quarter. CWM LLC raised its position in shares of MeiraGTx by 1,737.7% in the 1st quarter. CWM LLC now owns 8,674 shares of the company’s stock worth $59,000 after acquiring an additional 8,202 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of MeiraGTx by 390.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,797 shares of the company’s stock valued at $57,000 after purchasing an additional 7,005 shares during the period. Finally, FNY Investment Advisers LLC bought a new stake in shares of MeiraGTx during the 2nd quarter valued at about $61,000. 67.48% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Alexandria Forbes sold 47,500 shares of MeiraGTx stock in a transaction that occurred on Tuesday, October 7th. The shares were sold at an average price of $8.39, for a total transaction of $398,525.00. Following the sale, the chief executive officer directly owned 1,313,983 shares in the company, valued at $11,024,317.37. This trade represents a 3.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Richard Giroux sold 24,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 21st. The shares were sold at an average price of $8.87, for a total transaction of $212,880.00. Following the completion of the transaction, the chief financial officer owned 829,494 shares of the company’s stock, valued at approximately $7,357,611.78. This trade represents a 2.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 7.50% of the stock is owned by company insiders.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.